Amerikanische Gesellschaft für Hirudotherapie

Spasticity Post-Spinal Cord Injury (Investigational Adjunct)

Investigational adjunct for muscular spasticity after SCI; no RCT support; baclofen (oral or intrathecal) and physiotherapy remain primary.

Tier C — InvestigationalInvestigativLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Patienten-Zusammenfassung

Ist dies FDA-zugelassen fuer diese Anwendung?
Not FDA-cleared for spasticity after spinal cord injury. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
Welche Evidenz existiert?
Tier C (investigational). No RCT evidence. Evidence-based first-line management is structured physical and occupational therapy with stretching, oral antispasmodics (baclofen, tizanidine, dantrolene), and for refractory spasticity intrathecal baclofen pump, botulinum toxin injection, or selective dorsal rhizotomy. Triggers (UTI, pressure injury, constipation) must be addressed first.
Hauptrisiken
  • Bleeding from each bite site for 6 to 10 hours after the leech detaches
  • Iron-deficiency anemia from cumulative blood loss across multiple sessions
  • Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
  • Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
  • Permanent Y-shaped bite-mark scars or hyperpigmentation at attachment sites
  • Local pain, bruising, swelling, or itching for 1 to 3 days after each session
  • Autonomic dysreflexia in patients with injuries at T6 or above — sessions can trigger dangerous blood pressure surges
  • Risk of pressure injury at bite sites in patients with sensory impairment
Wer dies nicht in Betracht ziehen sollte
  • Patients with spinal cord injury at T6 or above without a clear autonomic dysreflexia monitoring plan
  • Patients with active UTI, pressure injury, constipation, or other spasticity triggers (treat those first)
  • Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran, heparin, or daily aspirin used for medical reasons
  • People with hemophilia or any other inherited bleeding disorder
  • Patients with severe anemia (hemoglobin under 10 g/dL)
  • People with an active infection at the planned application site
  • Patients who are pregnant or breastfeeding (relative contraindication; insufficient safety data)
Was Sie Ihren Kliniker fragen sollten
  • Has a recent UTI, pressure injury, ingrown toenail, or constipation episode been ruled out as the spasticity trigger?
  • Am I on optimal oral antispasmodic doses?
  • Have intrathecal baclofen, botulinum toxin, or surgical options been discussed?
  • What is the autonomic dysreflexia monitoring plan during and after sessions?
  • How will sensory loss affect bite-site monitoring for pressure or infection?
  • What is the published evidence in spinal cord injury spasticity specifically?
Wann dringende medizinische Versorgung suchen
  • Bleeding from a bite site that soaks through more than one dressing per hour
  • Bleeding that continues more than 24 hours after the leech detached
  • Spreading redness, warmth, swelling, pus, or red streaks around any bite site
  • Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
  • Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
  • Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
  • Sudden severe headache, sweating above the level of injury, slow heart rate, severe high blood pressure (autonomic dysreflexia — emergency)
  • Spread of redness or new wound at a numb area

Was dies NICHT bedeutet

  • It does not mean leech therapy is FDA-cleared for spasticity — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
  • It does not replace structured PT/OT, antispasmodic medication, or intrathecal baclofen for severe cases.
  • It does not modify the underlying spinal cord injury.
  • It does not address spasticity triggers (UTI, pressure injury, bowel issues) — those must be treated separately.
  • It does not have controlled-trial evidence in this population.

Clinical Profile

Category
neurological
ICD-10
G82.20, G82.21, G82.22, G81.10
Safety tier
high

Evidence Summary

Spasticity affects a large majority of patients with spinal cord injury and is managed per Consortium for Spinal Cord Medicine guidelines with stretching, positioning, oral antispastic agents (baclofen, tizanidine), botulinum toxin for focal spasticity, and intrathecal baclofen for severe diffuse spasticity. No controlled clinical trial or case report of leech therapy for post-SCI spasticity has been published; use is investigational only. Any peripheral tone reduction is speculative, and the cortical and spinal reflex contributions that drive spasticity would not be addressed by local leech application.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Key Trials

  1. Krashenyuk AI (2010)0

Contraindications

  • Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
  • Hemophilia or other bleeding disorder
  • Severe anemia (Hb <10 g/dL)
  • Active bacteremia or sepsis
  • Known hypersensitivity to leech salivary proteins
  • Pregnancy (relative — first/third trimester)
  • Immunocompromised state with severe neutropenia
  • Active deep vein thrombosis (acute phase <2 weeks)
  • Critical limb ischemia (ABI <0.4)
  • Pressure injuries at proposed treatment sites
  • Autonomic dysreflexia (T6 or above SCI) without prophylaxis
  • Anticoagulation for venous thromboembolism prophylaxis
  • Concurrent botulinum toxin injection within 2 weeks

Related Conditions

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.

Spasticity Post-Spinal Cord Injury (Investigational Adjunct) — Hirudotherapy Evidence | ASH